Skip to main content

Advertisement

Log in

Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin’s lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The role of 18FDG-PET/CT during follow-up of patients affected by Hodgkin’s lymphoma (HL) in complete remission after treatment is not fully elucidated, since a wide use of 18F fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in this setting could be limited by a relative high rate of false-positive results. Herein, we summarize a retrospective analysis of 27 patients with Hodgkin’s lymphoma in complete remission after the first-line (n = 20) or salvage (n = 7) therapy receiving serial 18FDG-PET/CT scans during follow-up. Out of 165 scans, 13 were suspected for relapse, which was confirmed in seven patients. All relapses were correctly identified by 18FDG-PET/CT positivity, with a 100% sensitivity; false-positive rate was 46% and negative predictive value was 100%. True-positive findings were mostly associated with multiple sites, subdiaphragmatic involvement, and/or previous sites of disease. According to our results, we conclude that performing routine PET/CT scan during follow-up of those patients who are at high risk of relapse would be advisable, although caution must be adopted when interpreting PET/CT results due to the relatively high rate of false-positive findings. If FDG abnormal uptake is present at multiple nodal sites, subdiaphragmatic lymph nodes, or previous sites of disease, histological verification of PET abnormal findings is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zinzani PL, Tani M, Trisolini R et al (2007) Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 92:771–777. doi:10.3324/haematol.10798

    Article  PubMed  Google Scholar 

  2. Isasi CR, Lu P, Blaufox MD (2005) A meta-analysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066–1074. doi:10.1002/cncr.21253

    Article  PubMed  Google Scholar 

  3. Rigacci L, Vitolo U, Nassi L et al (2007) Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86:897–903. doi:10.1007/s00277-007-0356-9

    Article  PubMed  Google Scholar 

  4. Schaefer NG, Strobel K, Taverna C et al (2007) Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med 34:60–67. doi:10.1007/s00259-006-0238-8

    Article  Google Scholar 

  5. Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N et al (2006) Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 135:293–302. doi:10.1111/j.1365-2141.2006.06284.x

    Article  PubMed  Google Scholar 

  6. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian–Danish study. J Clin Oncol 25:3746–3752. doi:10.1200/JCO.2007.11.6525

    Article  CAS  PubMed  Google Scholar 

  7. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59. doi:10.1182/blood-2005-06-2252

    Article  CAS  PubMed  Google Scholar 

  8. Haioun C, Itti E, Rahmouni E et al (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381. doi:10.1182/blood-2005-01-0272

    Article  CAS  PubMed  Google Scholar 

  9. Querellou S, Valette F, Bodet-Milin C et al (2006) FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease. Ann Hematol 85:759–767. doi:10.1007/s00277-006-0151-z

    Article  CAS  PubMed  Google Scholar 

  10. Schot BW, Zijlstra JM, Sluiter WJ et al (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in relapsed lymphoma. Blood 109:486–491. doi:10.1182/blood-2005-11-006957

    Article  CAS  PubMed  Google Scholar 

  11. Spaepen K, Stroobants S, Dupont P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419

    CAS  PubMed  Google Scholar 

  12. Spaepen K, Stroobants S, Dupont P et al (2001) Can positron emission tomography with [(18) F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272–278. doi:10.1046/j.1365-2141.2001.03169.x

    Article  CAS  PubMed  Google Scholar 

  13. Weihrauch MR, Re D, Scheidhauer K et al (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930–2934. doi:10.1182/blood.V98.10.2930

    Article  CAS  PubMed  Google Scholar 

  14. Juweid ME, Stroobants S, Hoekstra O et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 25:571–578. doi:10.1200/JCO.2006.08.2305

    Article  PubMed  Google Scholar 

  15. Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989–3994. doi:10.1182/blood-2008-06-155820

    Article  CAS  PubMed  Google Scholar 

  16. Hutchings M, Loft A, Hansen M et al (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78:206–212. doi:10.1111/j.1600-0609.2006.00802.x

    Article  PubMed  Google Scholar 

  17. Jerusalem G, Beguin Y, Fassotte MF et al (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 14:123–130. doi:10.1093/annonc/mdg011

    Article  CAS  PubMed  Google Scholar 

  18. Schaefer HG, Taverna C, Strobel K et al (2007) Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy - is biopsy of FDG-avid lesions still needed? Radiology 244:257–262. doi:10.1148/radiol.2441060810

    Article  PubMed  Google Scholar 

  19. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586. doi:10.1200/JCO.2006.09.2403

    Article  PubMed  Google Scholar 

  20. Crocchiolo R, Canevari C, Assanelli A et al (2008) Pre-transplant FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 49:727–733. doi:10.1080/10428190701885545

    Article  CAS  PubMed  Google Scholar 

  21. Cremerius U, Fabry U, Wildberger JE et al (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant 30:103–111. doi:10.1038/sj.bmt.1703607

    Article  CAS  PubMed  Google Scholar 

  22. Schot BW, Pruim J, van Imhoff GW et al (2006) The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 91:490–495

    PubMed  Google Scholar 

  23. Filmont JE, Czernin J, Yap C et al (2003) Value of F-18-fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124:608–613. doi:10.1378/chest.124.2.608

    Article  PubMed  Google Scholar 

  24. Svoboda J, Andreadis C, Elstrom R et al (2006) Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 38:211–216. doi:10.1038/sj.bmt.1705416

    Article  CAS  PubMed  Google Scholar 

  25. Derenzini E, Musuraca G, Fanti S et al (2008) Pre-transplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 113:2496–2503. doi:10.1002/cncr.23861

    Article  PubMed  Google Scholar 

  26. Dodero A, Crocchiolo R, Patriarca F et al (2007) Prognostic value of positron emission tomography (PET) scan in patients with relapsed Hodgkin lymphoma or aggressive non-Hodgkin lymphoma receiving salvage chemotherapy followed by reduced-intensity allogeneic stem cell transplantation. Blood Abs#3039

  27. Torrey MJ, Poen JC, Hoppe RT (1997) Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 15:1123–1130

    CAS  PubMed  Google Scholar 

  28. Radford JA, Eardley A, Woodman C et al (1997) Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ 314:343–346

    CAS  PubMed  Google Scholar 

  29. Baron F, Storb R, Storer BE et al (2006) Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 24:4150–4157. doi:10.1200/JCO.2006.06.9914

    Article  PubMed  Google Scholar 

  30. Corradini P, Dodero A, Farina L et al (2007) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 22:2316–2323. doi:10.1038/sj.leu.2404822

    Article  Google Scholar 

  31. Freytes CO, Loberiza FR, Rizzo JD et al (2004) Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 104:3797–3803. doi:10.1182/blood-2004-01-0231

    Article  CAS  PubMed  Google Scholar 

  32. Levine JM, Weiner M, Kelly KM (2006) Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 28:711–714. doi:10.1097/01.mph.0000243648.66734.eb

    Article  PubMed  Google Scholar 

  33. Meany HJ, Gidvani VK, Minniti CP (2007) Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 48:399–402. doi:10.1002/pbc.20797

    Article  PubMed  Google Scholar 

  34. Zinzani PL, Stefoni V, Tani M et al (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27:1781–1787

    Article  PubMed  Google Scholar 

  35. Sonet A, Graux C, Nollevaux NC et al (2007) Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol 86:9–15. doi:10.1007/s00277-006-0167-4

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to all doctors and nurses involved in the care of patients of the Hematology and BMT Unit and Nuclear Medicine Division.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Crocchiolo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crocchiolo, R., Fallanca, F., Giovacchini, G. et al. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin’s lymphoma. Ann Hematol 88, 1229–1236 (2009). https://doi.org/10.1007/s00277-009-0752-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-009-0752-4

Keywords

Navigation